Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Regional Heterogeneity in 3D Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy: A Cardiovascular CMR Tagging Substudy to the Life Study.

Biederman RW, Young AA, Doyle M, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ.

J Biomed Sci Eng. 2015 Mar 1;8(3):213-225. Epub 2015 Mar 26.

2.

Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome.

Hage FG, Perry G, Heo J, Iskandrian AE.

Am J Cardiol. 2010 Mar 15;105(6):839-43. doi: 10.1016/j.amjcard.2009.11.042.

PMID:
20211328
3.

Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study.

Ahmed MI, Ekundayo OJ, Mujib M, Campbell RC, Sanders PW, Pitt B, Perry GJ, Bakris G, Aban I, Love TE, Aronow WS, Ahmed A.

Int J Cardiol. 2010 Oct 29;144(3):383-8. doi: 10.1016/j.ijcard.2009.04.041. Epub 2009 Jun 5.

4.

The scope of coronary heart disease in patients with chronic kidney disease.

Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE.

J Am Coll Cardiol. 2009 Jun 9;53(23):2129-40. doi: 10.1016/j.jacc.2009.02.047. Review.

5.

Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study.

Ekundayo OJ, Adamopoulos C, Ahmed MI, Pitt B, Young JB, Fleg JL, Love TE, Sui X, Perry GJ, Siscovick DS, Bakris G, Ahmed A.

Int J Cardiol. 2010 May 28;141(2):167-74. doi: 10.1016/j.ijcard.2008.11.195. Epub 2009 Jan 9.

6.

Serial evaluations of myocardial infarct size after alcohol septal ablation in hypertrophic cardiomyopathy and effects of the changes on clinical status and left ventricular outflow pressure gradients.

Aqel RA, Hage FG, Zohgbi GJ, Tabereaux PB, Lawson D, Heo J, Perry G, Epstein AE, Dell' Italia LJ, Iskandrian AE.

Am J Cardiol. 2008 May 1;101(9):1328-33. doi: 10.1016/j.amjcard.2007.12.042. Epub 2008 Mar 10.

PMID:
18435966
7.

Feasibility of primary clot extraction prior to percutaneous coronary intervention in acute myocardial infarction.

Aqel R, Zoghbi G, Hage F, Philips G, Perry G, Iskandrian A, Dell'Italia L.

Catheter Cardiovasc Interv. 2008 Jun 1;71(7):870-6. doi: 10.1002/ccd.21465.

PMID:
18383164
8.

Systolic dysfunction portends increased mortality among those waiting for renal transplant.

de Mattos AM, Siedlecki A, Gaston RS, Perry GJ, Julian BA, Kew CE 2nd, Deierhoi MH, Young C, Curtis JJ, Iskandrian AE.

J Am Soc Nephrol. 2008 Jun;19(6):1191-6. doi: 10.1681/ASN.2007040503. Epub 2008 Mar 27.

9.

Transthoracic echocardiography guided procedures in the catheterization laboratory.

Aqel RA, Hage FG, Cogar B, Burri M, Wells B, Allison S, Zoghbi GJ, Perry G, Bittner V, Fan P, Nanda NC.

Echocardiography. 2007 Oct;24(9):1000-7. Review. No abstract available.

PMID:
17894583
10.

Predictors of survival in patients with end-stage renal disease evaluated for kidney transplantation.

Hage FG, Smalheiser S, Zoghbi GJ, Perry GJ, Deierhoi M, Warnock D, Iskandrian AE, de Mattos AM, Aqel RA.

Am J Cardiol. 2007 Sep 15;100(6):1020-5. Epub 2007 Jul 5.

PMID:
17826390
11.

VALIDD should not invalidate angiotensin-receptor blockers.

Ahmed A, Perry GJ, Husain A.

Lancet. 2007 Jun 23;369(9579):2053-4. No abstract available.

PMID:
17586284
12.

Origin of all three major coronary arteries from the right sinus of Valsalva: clinical, angiographic, and magnetic resonance imaging findings and incidence in a select referral population.

Patel KB, Gupta H, Nath H, Aqel RA, Zoghbi GJ, Soto B, Perry GJ, Lloyd SG.

Catheter Cardiovasc Interv. 2007 Apr 1;69(5):711-8.

PMID:
17330267
13.

Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study.

Ahmed A, Rich MW, Sanders PW, Perry GJ, Bakris GL, Zile MR, Love TE, Aban IB, Shlipak MG.

Am J Cardiol. 2007 Feb 1;99(3):393-8. Epub 2006 Dec 8.

14.

Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis.

Ahmed A, Perry GJ, Fleg JL, Love TE, Goff DC Jr, Kitzman DW.

Am Heart J. 2006 Nov;152(5):956-66.

15.

Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.

Franco V, Chen YF, Feng JA, Li P, Wang D, Hasan E, Oparil S, Perry GJ.

Clin Exp Pharmacol Physiol. 2006 Sep;33(9):773-9.

PMID:
16922805
17.

Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling.

Franco V, Chen YF, Oparil S, Feng JA, Wang D, Hage F, Perry G.

Hypertension. 2004 Nov;44(5):746-50. Epub 2004 Sep 27.

18.

Impact of atrial fibrillation on mortality and readmission in older adults hospitalized with heart failure.

Ahmed A, Thornton P, Perry GJ, Allman RM, DeLong JF.

Eur J Heart Fail. 2004 Jun;6(4):421-6.

19.

Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse.

Mori T, Chen YF, Feng JA, Hayashi T, Oparil S, Perry GJ.

Cardiovasc Res. 2004 Mar 1;61(4):771-9.

PMID:
14985074
20.

Pressure-independent enhancement of cardiac hypertrophy in atrial natriuretic peptide-deficient mice.

Feng JA, Perry G, Mori T, Hayashi T, Oparil S, Chen YF.

Clin Exp Pharmacol Physiol. 2003 May-Jun;30(5-6):343-9.

PMID:
12859424

Supplemental Content

Loading ...
Support Center